Get Live Data
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Astrazeneca Share Price
  4. Astrazeneca Share Regulatory News
  5. Astrazeneca

Pin to quick picksAstrazeneca Regulatory News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
13,858.00    304.00 (2.24%)
Bid:
13,842.00
Ask:
13,846.00
Spread: 4.00 (0.029%)
Market Cap: £214.92b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Astrazeneca

1 Apr 2019 18:00

RNS Number : 7122U
FTSE Russell
01 April 2019
 

 

 

 

 

AstraZeneca (UK): Shares in Issue ChangeChanges in FTSE UK Index Series

01 April 2019

Following the receipt of updated shares in issue information for AstraZeneca (UK, constituent) as a result of a primary placing, please see details of affected indexes and effective dates below:

 

 

Index

Effective FromStart of Trading

FTSE 100 Index

04 April 2019

FTSE 350 Index

04 April 2019

FTSE All-Share Index

04 April 2019

FTSE 350 Higher Yield Index

04 April 2019

Techmark All Share Index

04 April 2019

 

 

 

 

 

 

 

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia

+1800 653 680

Hong Kong

+852 2164 3333

Japan

+81 3 4563 6346

London

+44 (0) 20 7866 1810

New York

+1866 551 0617

 

Alternatively please visit our website at www.ftserussell.com

Terms of Use | Copyright © 2019 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FTSSSDFDFFUSEEL
131415161718192021
Date   Source Headline
1st Apr 20197:00 amRNSSelumetinib gets Breakthrough Therapy Designation
29th Mar 20195:15 pmRNSResults of Placing
29th Mar 20197:00 amRNSProposed placing of new ordinary shares
29th Mar 20197:00 amRNSAZ and Daiichi Sankyo enter collaboration in novel
27th Mar 20197:00 amRNSForxiga approved in Japan for type-1 diabetes
25th Mar 20197:00 amRNSForxiga approved in Europe for type-1 diabetes
18th Mar 20197:00 amRNSUS FDA grants saracatinib ODD for IPF
14th Mar 201912:00 pmRNSNotice of AGM
12th Mar 201912:00 pmRNSDirector/PDMR Shareholding
6th Mar 20197:00 amRNSFiling of Form 20-F with SEC
5th Mar 201911:00 amRNSAnnual Financial Report
4th Mar 20194:04 pmRNSHolding(s) in Company
1st Mar 20193:00 pmRNSTotal Voting Rights
1st Mar 20191:45 pmRNSLynparza receives positive EU CHMP opinion
26th Feb 20197:00 amRNSLynparza significantly delayed disease progression
25th Feb 20197:00 amRNSBrilinta's PhIII THEMIS trial met primary endpoint
14th Feb 20197:00 amRNSAstraZeneca Full-Year and Q4 2018 Results
6th Feb 20197:00 amRNSUS FDA grants Fasenra Orphan Drug Designation
5th Feb 20197:05 amRNSUS FDA grants Breakthrough Therapy Designation
5th Feb 20197:00 amRNSEMA grants PRIME eligibility for MEDI8897
1st Feb 20193:00 pmRNSTotal Voting Rights
1st Feb 20191:17 pmRNSForxiga receives positive EU CHMP opinion
25th Jan 20192:00 pmRNSCompletion of divestment of US Synagis rights
7th Jan 20191:00 pmRNSAstraZeneca announces organisational changes
2nd Jan 20193:00 pmRNSTotal Voting Rights
20th Dec 20181:47 pmRNSBevespi Aerosphere approved in the EU for COPD
20th Dec 20187:05 amRNSLynparza meets primary endpoint in SOLO-3 trial
20th Dec 20187:00 amRNSPhase III ROCKIES and OLYMPUS roxadustat trials
19th Dec 20186:31 pmRNSFDA approves Lynparza as 1L maintenance therapy
18th Dec 20189:09 amRNSRoxadustat approved in China for the treatment of
14th Dec 20187:00 amRNSDirectorate Change
7th Dec 20187:00 amRNSUpdate on the Phase III EAGLE trial of Imfinzi
6th Dec 20187:00 amRNSDivestment of rights to Covis completed
4th Dec 20183:00 pmRNSDirector/PDMR Shareholding
3rd Dec 20184:00 pmRNSBlock listing Interim Review
3rd Dec 20184:00 pmRNSTotal Voting Rights
3rd Dec 20187:00 amRNSGrünenthal Agreement for Nexium, Vimovo Completed
26th Nov 20187:00 amRNSUS FDA grants Fasenra ODD for EGPA
16th Nov 20187:00 amRNSAstraZeneca provides update on Phase III MYSTIC
13th Nov 20187:00 amRNSAstraZeneca to divest US Synagis rights to Sobi
12th Nov 20187:05 amRNSUS FDA accepts regulatory submission for Lynparza
12th Nov 20187:00 amRNSFarxiga significantly reduced hospitalisation for
8th Nov 20187:00 amRNSAZN: Year-to-Date and Q3 2018 Results
6th Nov 20187:00 amRNSDivestment of rights to Covis Pharma
1st Nov 20183:00 pmRNSTotal Voting Rights
31st Oct 20189:45 amRNSAdditional financial information-Grünenthal deal
30th Oct 20187:00 amRNSGrünenthal Agreement for rights to Nexium, Vimovo
23rd Oct 20187:00 amRNSAstraZeneca Extends Innate Pharma Collaboration
22nd Oct 20187:00 amRNSLynparza shows 70% reduction in PFS ovarian cancer
19th Oct 20181:09 pmRNSCHMP positive opinion Bevespi Aerosphere
131415161718192021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
FAS
Fidelity Asian Values
LSE
-2.40%
CGT
Capital Gearing Trust
LSE
-0.19%
CASP
Caspian Sunrise
LSE
0.00%
THFA
Jh Fa Hy Ua
LSE
-0.46%
PVG
PVG.L
LSE
0.00%
Trending
ITM
Itm Power
LSE
-10.85%
GST
GSTechnologies
LSE
8.11%
PPP
Pennpetro Energy
LSE
0.00%
EZJ
easyJet
LSE
0.34%
NANO
Nanoco
LSE
-10.69%